Drug Type TCR-T Cell therapy |
Synonyms KRAS-Specific Autologous TCR-T Cells(Corregene Biotechnology) |
Target |
Action inhibitors |
Mechanism KRAS G12V inhibitors(GTPase KRas G12V inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 10 Jan 2025 | |
Colorectal Cancer | Phase 1 | - | 10 Jan 2025 | |
Non-Small Cell Lung Cancer | Phase 1 | - | 10 Jan 2025 | |
Pancreatic Cancer | Preclinical | China | 20 Jun 2023 |